High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection

JYH-CHIN YANGWang H.-L.CHUN-JUNG LINChen J.-D.Kao J.Y.CHIA-TUNG SHUNLu C.-W.Lin L.-C.BOR-RU LINMING-CHU CHANGYU-TING CHANGSHU-CHEN WEIMING-JIUM SHIEHYeh W.-C.Kuo J.-S.Leong Y.-L.CHIEN-CHIH TUNGWang T.-H.JAU-MIN WONG2022-03-042022-03-0420151542-3565https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927911344&doi=10.1016%2fj.cgh.2014.10.036&partnerID=40&md5=c1a08f6e844bb1bf05e86b8a6bbf4673https://scholars.lib.ntu.edu.tw/handle/123456789/596499The efficacy of treatment of Helicobacter pylori infection has decreased steadily because of increasing resistance to clarithromycin, metronidazole, and levofloxacin. Resistance to amoxicillin is generally low, and high intragastric pH increases the efficacy of amoxicillin, so we investigated whether a combination of a high-dose proton pump inhibitor and amoxicillin (dual therapy) was more effective than standard first-line or rescue therapies in eradicating H pylori. ? 2015 AGA Institute.[SDGs]SDG3amoxicillin; clarithromycin; levofloxacin; metronidazole; proton pump inhibitor; rabeprazole; urea c 13; antiinfective agent; proton pump inhibitor; abdominal disease; abdominal distress; adult; antibiotic resistance; Article; bacterial clearance; controlled study; cytochrome P450 2C19 gene; diarrhea; dizziness; drug efficacy; drug megadose; drug tolerability; drug treatment failure; dysgeusia; female; gene; genotype; Helicobacter infection; human; human tissue; intention to treat analysis; major clinical study; male; nausea; patient compliance; pruritus; randomized controlled trial; treatment outcome; unspecified side effect; adverse effects; aged; clinical trial; combination drug therapy; comparative study; drug effects; Helicobacter Infections; Helicobacter pylori; middle aged; multicenter study; procedures; prospective study; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment OutcomeHigh-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infectionjournal article10.1016/j.cgh.2014.10.036254605562-s2.0-84927911344